company|headline|link|homeurl|date
Atomwise (Private)|Sanofi signs $1.2B pact with Atomwise in latest high-value AI drug discovery deal|https://www.fiercebiotech.com/biotech/sanofi-signs-12b-pact-atomwise-latest-high-value-ai-drug-discovery-deal|https://www.atomwise.com|
Atomwise (Private)|Abe Heifets of Atomwise on How AI is Redefining Drug Discovery|https://brainsbehind.ai/atomwise/|https://www.atomwise.com|
Atomwise (Private)|Sanofi pays Atomwise $20 million in AI-enabled research pact|https://cen.acs.org/business/informatics/Sanofi-pays-Atomwise-20-million/100/i30|https://www.atomwise.com|
Atomwise (Private)|Sanofi, Atomwise Ink Potential $1B+ R&D Deal|https://www.biospace.com/article/atomwise-inks-potential-1-billion-plus-r-and-d-deal-with-sanofi/|https://www.atomwise.com|
Atomwise (Private)|Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise|https://pharmaphorum.com/news/diving-deeper-into-ai-discovery-sanofi-signs-5-drug-deal-with-atomwise/|https://www.atomwise.com|
Atomwise (Private)|A couple billion for Exscientia was only part of Sanofi’s AI ambitions, as the Big Pharma adds Atomwise to the table|https://endpts.com/a-couple-billion-for-exscientia-was-only-part-of-sanofis-ai-ambitions-as-the-big-pharma-adds-atomwise-to-the-table/|https://www.atomwise.com|
Atomwise (Private)|Sold on the New Machine|https://cen.acs.org/business/informatics/Sold-new-machine/100/i7|https://www.atomwise.com|
Relay Therapeutics|Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-second-quarter-2023-financial-results|https://ir.relaytx.com|August 8, 2023
Relay Therapeutics|Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announce-second-quarter-2023-financial|https://ir.relaytx.com|August 1, 2023
Relay Therapeutics|Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-full-dose-escalation-data-rly-4008|https://ir.relaytx.com|May 25, 2023
Relay Therapeutics|Relay Therapeutics to Participate in Two Upcoming Investor Conferences|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-participate-two-upcoming-investor-6|https://ir.relaytx.com|May 24, 2023
Relay Therapeutics|Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-first-quarter-2023-financial-results|https://ir.relaytx.com|May 4, 2023
Relay Therapeutics|Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announce-first-quarter-2023-financial-results|https://ir.relaytx.com|April 27, 2023
Relay Therapeutics|Relay Therapeutics to Participate in Two Upcoming Investor Conferences|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-participate-two-upcoming-investor-3|https://ir.relaytx.com|April 19, 2023
Relay Therapeutics|Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-initial-clinical-data-demonstrating|https://ir.relaytx.com|April 18, 2023
Relay Therapeutics|Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-present-initial-clinical-data-rly-2608-aacr|https://ir.relaytx.com|March 6, 2023
Relay Therapeutics|Relay Therapeutics to Participate in Two Upcoming Investor Conferences|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-participate-two-upcoming-investor-5|https://ir.relaytx.com|March 1, 2023
Relay Therapeutics|Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-fourth-quarter-and-full-year-2022|https://ir.relaytx.com|February 23, 2023
Relay Therapeutics|Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announce-fourth-quarter-and-full-year-2022|https://ir.relaytx.com|February 16, 2023
Relay Therapeutics|"Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day"|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-participate-guggenheim-healthcare-talks|https://ir.relaytx.com|February 2, 2023
Relay Therapeutics|Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference|https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-present-41st-annual-jp-morgan-healthcare|https://ir.relaytx.com|January 3, 2023
Insilico Medicine (Private)|None|https://insilico.com|https://insilico.com|
Benevolent AI|Press release                                        21 Jun 2023 Board Change Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/board-change/|https://www.benevolent.com|June 21, 2023
Benevolent AI|Press release                                        05 Jun 2023 BenevolentAI progresses BEN-34712 for the potential treatment of ALS into IND-enabling studies Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-progresses-ben-34712-potential-treatment-als-ind-enabling-studies/|https://www.benevolent.com|June 05, 2023
Benevolent AI|Press release                                        31 May 2023 New preclinical data on AI-generated target identified in BenevolentAI and AstraZeneca collaboration presented at ATS 2023 Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/new-preclinical-data-ai-generated-target-identified-benevolentai-and-astrazeneca-collaboration-presented-ats-2023/|https://www.benevolent.com|May 31, 2023
Benevolent AI|Press release                                        25 May 2023 BenevolentAI unveils strategic plan to position the Company for a new era in AI Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-unveils-strategic-plan-position-company-new-era-ai/|https://www.benevolent.com|May 25, 2023
Benevolent AI|Press release                                        16 May 2023 9xchange joins forces with BenevolentAI to integrate its AI technology into its innovative biopharma marketplace Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/9xchange-joins-forces-benevolentai-integrate-its-ai-technology-its-innovative-biopharma-marketplace/|https://www.benevolent.com|May 16, 2023
Benevolent AI|Press release                                        04 May 2023 Result of Annual General Meeting Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/result-annual-general-meeting/|https://www.benevolent.com|May 04, 2023
Benevolent AI|Press release                                        05 Apr 2023 BenevolentAI announces top-line Phase IIa results for its topical pan-Trk inhibitor BEN-2293 (1%) in mild-to-moderate atopic dermatitis Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-top-line-phase-iia-results-its-topical-pan-trk-inhibitor-ben-2293-1-mild-moderate-atopic-dermatitis/|https://www.benevolent.com|April 05, 2023
Benevolent AI|Press release                                        22 Mar 2023 BenevolentAI strengthens its Board of Directors with the appointment of digital innovation expert Marcello Damiani Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-strengthens-its-board-directors-appointment-digital-innovation-expert-marcello-damiani/|https://www.benevolent.com|March 22, 2023
Benevolent AI|Press release                                        16 Mar 2023 BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022 Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-unaudited-preliminary-results-year-ended-31-december-2022/|https://www.benevolent.com|March 16, 2023
Benevolent AI|Press release                                        16 Feb 2023 Notice of Preliminary Results Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/notice-preliminary-results/|https://www.benevolent.com|February 16, 2023
Benevolent AI|Press release                                        15 Feb 2023 BenevolentAI to present at the Cowen 43rd Annual Health Care Conference Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-present-cowen-43rd-annual-health-care-conference/|https://www.benevolent.com|February 15, 2023
Benevolent AI|In the media                                        16 Jan 2023 The Secret Sauce To BenevolentAI’s Ongoing Success Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/secret-sauce-benevolentais-ongoing-success/|https://www.benevolent.com|January 16, 2023
Benevolent AI|Press release                                        21 Dec 2022 BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-submits-cta-ben-8744-oral-pde10-inhibitor-first-class-treatment-ulcerative-colitis/|https://www.benevolent.com|December 21, 2022
Benevolent AI|Press release                                        01 Dec 2022 BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-present-41st-annual-jp-morgan-healthcare-conference/|https://www.benevolent.com|December 01, 2022
Benevolent AI|Press release                                        04 Nov 2022 BenevolentAI To Present At Jefferies Investor Conference In November Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-present-jefferies-investor-conference-november/|https://www.benevolent.com|November 04, 2022
Benevolent AI|Press release                                        06 Oct 2022 BenevolentAI Achieves Further Milestones In AI-Enabled Target Identification Collaboration With AstraZeneca Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-achieves-further-milestones-ai-enabled-target-identification-collaboration-astrazeneca/|https://www.benevolent.com|October 06, 2022
Benevolent AI|Press release                                        27 Sep 2022 Analyst / Investor Event Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/analyst-investor-event/|https://www.benevolent.com|September 27, 2022
Benevolent AI|Press release                                        27 Sep 2022 Interim Results For The Six Months Ended 30 June 2022 Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/interim-results-six-months-ended-30-june-2022/|https://www.benevolent.com|September 27, 2022
Benevolent AI|Press release                                        16 Sep 2022 Analyst / Investor Event And Interim Results Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/analyst-investor-event-and-interim-results/|https://www.benevolent.com|September 16, 2022
Benevolent AI|Press release                                        26 Aug 2022 Notice Of Interim Results And Analyst / Investor Event Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/notice-interim-results-and-analyst-investor-event/|https://www.benevolent.com|August 26, 2022
Benevolent AI|Press release                                        06 Jul 2022 BenevolentAI Appoints GSK Drug Discovery Veteran Dr Nicola Richmond As Vice President Of AI Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-appoints-gsk-drug-discovery-veteran-dr-nicola-richmond-vice-president-ai/|https://www.benevolent.com|July 06, 2022
Benevolent AI|Press release                                        10 Jun 2022 BenevolentAI Announces Participation In Upcoming Investor Conferences Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-participation-upcoming-investor-conferences/|https://www.benevolent.com|June 10, 2022
Benevolent AI|Press release                                        25 May 2022 BenevolentAI Announces Board Changes Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-board-changes/|https://www.benevolent.com|May 25, 2022
Benevolent AI|Press release                                        17 May 2022 BenevolentAI Achieves Third Milestone In Its AI-Enabled Drug Discovery Collaboration With AstraZeneca Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-achieves-third-milestone-its-ai-enabled-drug-discovery-collaboration-astrazeneca/|https://www.benevolent.com|May 17, 2022
Benevolent AI|Press release                                        25 Apr 2022 BenevolentAI Begins Trading On Euronext Amsterdam Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-begins-trading-euronext-amsterdam/|https://www.benevolent.com|April 25, 2022
Benevolent AI|Press release                                        21 Apr 2022 BenevolentAI Joins The World Economic Forum’s Global Innovators Community Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-joins-world-economic-forums-global-innovators-community/|https://www.benevolent.com|April 21, 2022
Benevolent AI|Press release                                        20 Apr 2022 DNDi And BenevolentAI Collaborate To Accelerate Life-Saving Drug Discovery Research In Dengue Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/dndi-and-benevolentai-collaborate-accelerate-life-saving-drug-discovery-research-dengue/|https://www.benevolent.com|April 20, 2022
Benevolent AI|In the media                                        20 Mar 2022 Will AI turbocharge the hunt for new drugs? Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/will-ai-turbocharge-hunt-new-drugs/|https://www.benevolent.com|March 20, 2022
Benevolent AI|Press release                                        04 Mar 2022 RECOVERY Trial Results Demonstrate Baricitinib Reduces Deaths In Hospitalised COVID-19 Patients Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/recovery-trial-results-demonstrate-baricitinib-reduces-deaths-hospitalised-covid-19-patients/|https://www.benevolent.com|March 04, 2022
Benevolent AI|Press release                                        03 Feb 2022 BenevolentAI Partners With The Helix Group At Stanford University To Advance Research On AI-Driven Drug Discovery Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-partners-helix-group-stanford-university-advance-research-ai-driven-drug-discovery/|https://www.benevolent.com|February 03, 2022
Benevolent AI|Press release                                        21 Jan 2022 BenevolentAI Appoints Daniel Neil As Chief Technology Officer Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-appoints-daniel-neil-chief-technology-officer/|https://www.benevolent.com|January 21, 2022
Benevolent AI|Press release                                        13 Jan 2022 BenevolentAI Announces 3-Year Collaboration Expansion With AstraZeneca Focused On Systemic Lupus Erythematosus And Heart Failure Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-3-year-collaboration-expansion-astrazeneca-focused-systemic-lupus-erythematosus-and-heart-failure/|https://www.benevolent.com|January 13, 2022
Benevolent AI|In the media                                        13 Jan 2022 AstraZeneca doubles down on BenevolentAI drug hunting partnership, adding heart failure, lupus targets Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/astrazeneca-doubles-down-benevolentai-drug-hunting-partnership-adding-heart-failure-lupus-targets/|https://www.benevolent.com|January 13, 2022
Benevolent AI|Press release                                        06 Jan 2022 BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-present-40th-annual-jp-morgan-healthcare-conference/|https://www.benevolent.com|January 06, 2022
Benevolent AI|Press release                                        15 Dec 2021 BenevolentAI Achieves Second Major Collaboration Milestone With Novel Idiopathic Pulmonary Fibrosis Target Selected For AstraZeneca’s Portfolio Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-achieves-second-major-collaboration-milestone-novel-idiopathic-pulmonary-fibrosis-target-selected-astrazenecas-port/|https://www.benevolent.com|December 15, 2021
Benevolent AI|Press release                                        14 Oct 2021 BenevolentAI Identifies Novel Target For Ulcerative Colitis And Advances Candidate To IND/CTA-Enabling Studies Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-identifies-novel-target-ulcerative-colitis-and-advances-candidate-indcta-enabling-studies/|https://www.benevolent.com|October 14, 2021
Benevolent AI|Press release                                        09 Sep 2021 BenevolentAI Appoints Dr John Orloff To Its Board Of Directors Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-appoints-dr-john-orloff-its-board-directors/|https://www.benevolent.com|September 09, 2021
Benevolent AI|In the media                                        08 Aug 2021 How tech is changing healthcare Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/how-tech-changing-healthcare/|https://www.benevolent.com|August 08, 2021
Benevolent AI|Press release                                        09 Jul 2021 BenevolentAI Announces The Appointment Of Biopharma Luminary Dr François Nader As Chairman Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-appointment-biopharma-luminary-dr-francois-nader-chairman/|https://www.benevolent.com|July 09, 2021
Benevolent AI|Press release                                        05 May 2021 Baricitinib, First Identified By BenevolentAI As A COVID-19 Treatment, Is Granted Emergency Use In India In Response To Its Escalating Crisis Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/baricitinib-first-identified-benevolentai-covid-19-treatment-granted-emergency-use-india-response-its-escalating-crisis/|https://www.benevolent.com|May 05, 2021
Benevolent AI|Press release                                        08 Apr 2021 Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38% Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/data-eli-lillys-cov-barrier-trial-shows-baricitinib-reduced-deaths-hospitalised-covid-19-patients-38/|https://www.benevolent.com|April 08, 2021
Benevolent AI|Press release                                        08 Mar 2021 BenevolentAI Named As One Of Fierce Medtech’s Fierce 15 Of 2020 Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-named-one-fierce-medtechs-fierce-15-2020/|https://www.benevolent.com|March 08, 2021
Benevolent AI|Press release                                        11 Feb 2021 BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-first-patient-dosed-its-atopic-dermatitis-clinical-trial/|https://www.benevolent.com|February 11, 2021
Benevolent AI|Press release                                        27 Jan 2021 BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-and-astrazeneca-achieve-collaboration-milestone-novel-ai-generated-chronic-kidney-disease-target/|https://www.benevolent.com|January 27, 2021
Benevolent AI|In the media                                        27 Jan 2021 AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/astrazeneca-scores-new-goal-pipeline-front-adding-its-first-ai-generated-target-portfolio/|https://www.benevolent.com|January 27, 2021
Benevolent AI|Press release                                        20 Nov 2020 FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/fda-grants-emergency-use-authorisation-baricitinib-hospitalised-covid-19-patients-nine-months-after-initial-hypothesis-was-publi/|https://www.benevolent.com|November 20, 2020
Benevolent AI|Press release                                        03 Nov 2020 Sir Nigel Shadbolt joins BenevolentAI as a non-executive director Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/sir-nigel-shadbolt-joins-benevolentai-non-executive-director/|https://www.benevolent.com|November 03, 2020
Benevolent AI|Press release                                        09 Oct 2020 NIAID releases additional data validating BenevolentAI’s hypothesis for baricitinib as a treatment for COVID-19 patients in large-scale randomised control trial Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/niaid-releases-additional-data-validating-benevolentais-hypothesis-baricitinib-treatment-covid-19-patients-large-scale-randomise/|https://www.benevolent.com|October 09, 2020
Benevolent AI|Press release                                        01 Oct 2020 BenevolentAI Welcomes Professor Russ Altman As Scientific Advisor Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-welcomes-professor-russ-altman-scientific-advisor/|https://www.benevolent.com|October 01, 2020
Benevolent AI|Press release                                        14 Sep 2020 BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentais-platform-derived-hypothesis-covid-19-treatment-validated-us-niaid-randomised-control-trial/|https://www.benevolent.com|September 14, 2020
Benevolent AI|Press release                                        01 Jul 2020 Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19 Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/clinical-data-validates-benevolentais-ai-predicted-hypothesis-baricitinib-potential-treatment-covid-19/|https://www.benevolent.com|July 01, 2020
Benevolent AI|In the media                                        01 Jul 2020 COVID-19 And AI: An Editorial Review In EMBO From Michael B. Schultz, Daniel Vera, David A. Sinclair Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/covid-19-and-ai-editorial-review-embo-michael-b-schultz-daniel-vera-david-sinclair/|https://www.benevolent.com|July 01, 2020
Benevolent AI|Press release                                        10 Apr 2020 Potential treatment for COVID-19 identified by BenevolentAI enters randomised clinical trial Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/potential-treatment-covid-19-identified-benevolentai-enters-randomised-clinical-trial/|https://www.benevolent.com|April 10, 2020
Benevolent AI|In the media                                        26 Feb 2020 MIT Technology Review names BenevolentAI as a top 10 breakthrough tech Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/mit-technology-review-names-benevolentai-top-10-breakthrough-tech/|https://www.benevolent.com|February 26, 2020
Benevolent AI|Press release                                        12 Feb 2020 BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-scientific-collaboration-uc-san-diego-investigate-cerebral-cavernous-malformations/|https://www.benevolent.com|February 12, 2020
Benevolent AI|Press release                                        17 Sep 2019 BenevolentAI announces $90 million investment from Temasek Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-90-million-investment-temasek/|https://www.benevolent.com|September 17, 2019
Benevolent AI|Press release                                        04 Sep 2019 BenevolentAI announces agreement with leading healthcare company to leverage BenevolentAI’s technology platform Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/benevolentai-announces-agreement-leading-healthcare-company-leverage-benevolentais-technology-platform/|https://www.benevolent.com|September 04, 2019
Benevolent AI|Press release                                        04 Aug 2019 Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/neuropore-therapies-and-benevolentai-enter-strategic-collaboration-discover-novel-therapeutics-through-application-artificial-in/|https://www.benevolent.com|August 04, 2019
Benevolent AI|Press release                                        29 Apr 2019 AstraZeneca starts artificial intelligence collaboration to accelerate drug discovery Read more|https://www.benevolent.com/news-and-media/press-releases-and-in-media/astrazeneca-starts-artificial-intelligence-collaboration-accelerate-drug-discovery/|https://www.benevolent.com|April 29, 2019
Exscientia|Exscientia Business Update for Second Quarter and First Half of 2023|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Business-Update-for-Second-Quarter-and-First-Half-of-2023/default.aspx|https://investors.exscientia.ai|08/10/2023
Exscientia|Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Report-Second-Quarter-2023-Financial-Results-on-August-10-2023/default.aspx|https://investors.exscientia.ai|08/03/2023
Exscientia|Exscientia Initiates Prospective Observational Study in Ovarian Cancer|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Initiates-Prospective-Observational-Study-in-Ovarian-Cancer/default.aspx|https://investors.exscientia.ai|07/18/2023
Exscientia|First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours|https://investors.exscientia.ai/press-releases/press-release-details/2023/First-Patient-Enrolled-in-Phase-12-ELUCIDATE-Trial-Assessing-GTAEXS617-in-Advanced-Solid-Tumours/default.aspx|https://investors.exscientia.ai|07/10/2023
Exscientia|Exscientia Announces Expansion of its Technology Leadership Team|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-Expansion-of-its-Technology-Leadership-Team/default.aspx|https://investors.exscientia.ai|06/29/2023
Exscientia|Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Present-at-the-Goldman-Sachs-44th-Annual-Global-Healthcare-Conference/default.aspx|https://investors.exscientia.ai|06/06/2023
Exscientia|Exscientia Business Update for First Quarter 2023|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Business-Update-for-First-Quarter-2023/default.aspx|https://investors.exscientia.ai|05/24/2023
Exscientia|"Exscientia Highlights ""The Future of AI-enabled Drug Discovery"" at SLAS Europe"|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Highlights-The-Future-of-AI-enabled-Drug-Discovery-at-SLAS-Europe/default.aspx|https://investors.exscientia.ai|05/22/2023
Exscientia|Professor Andrew L. Hopkins elected Fellow of the Academy of Medical Sciences|https://investors.exscientia.ai/press-releases/press-release-details/2023/Professor-Andrew-L.-Hopkins-elected-Fellow-of-the-Academy-of-Medical-Sciences/default.aspx|https://investors.exscientia.ai|05/17/2023
Exscientia|Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Report-First-Quarter-2023-Financial-Results-on-May-24-2023/default.aspx|https://investors.exscientia.ai|05/17/2023
Exscientia|Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-Sixth-Molecule-Created-Through-Generative-AI-Platform-to-Enter-Clinical-Stage/default.aspx|https://investors.exscientia.ai|05/15/2023
Exscientia|Professor Andrew L. Hopkins elected Fellow of the Royal Society|https://investors.exscientia.ai/press-releases/press-release-details/2023/Professor-Andrew-L.-Hopkins-elected-Fellow-of-the-Royal-Society/default.aspx|https://investors.exscientia.ai|05/10/2023
Exscientia|Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Appoints-Harvard-Professor-Franziska-Michor-Ph.D.-to-Board-of-Directors/default.aspx|https://investors.exscientia.ai|05/03/2023
Exscientia|Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development|https://investors.exscientia.ai/press-releases/press-release-details/2023/Data-Presented-at-AACR-2023-Highlights-Exscientias-Clinical-and-Preclinical-Development/default.aspx|https://investors.exscientia.ai|04/19/2023
Exscientia|Exscientia Business and Financial Update for the Full Year 2022|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Business-and-Financial-Update-for-the-Full-Year-2022/default.aspx|https://investors.exscientia.ai|03/23/2023
Exscientia|Exscientia to Report Full Year 2022 Financial Results on March 23, 2023|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Report-Full-Year-2022-Financial-Results-on-March-23-2023/default.aspx|https://investors.exscientia.ai|03/16/2023
Exscientia|Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Present-Data-Highlighting-Pipeline-and-Precision-Medicine-Platform-at-AACR/default.aspx|https://investors.exscientia.ai|03/15/2023
Exscientia|Exscientia Announces Expansion of its Precision Oncology Pipeline|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-Expansion-of-its-Precision-Oncology-Pipeline/default.aspx|https://investors.exscientia.ai|03/14/2023
Exscientia|Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-Collaboration-with-Charit-to-Advance-Development-of-Precision-Medicine-Platform/default.aspx|https://investors.exscientia.ai|03/07/2023
Exscientia|Exscientia to Present at Upcoming Investor Conferences in March|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-to-Present-at-Upcoming-Investor-Conferences-in-March/default.aspx|https://investors.exscientia.ai|02/22/2023
Exscientia|Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318|https://investors.exscientia.ai/press-releases/press-release-details/2023/Exscientia-Announces-First-in-Human-Study-for-Bristol-Myers-Squibb-In-Licensed-PKC-Theta-Inhibitor-EXS4318/default.aspx|https://investors.exscientia.ai|02/02/2023
Valo Health|Valo Health to Participate in the Jefferies Global Healthcare Conference|https://www.valohealth.com/press/valo-health-to-participate-in-the-jefferies-global-healthcare-conference|https://www.valohealth.com|
Recursion|Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds|https://ir.recursion.com/news-releases/news-release-details/recursion-bridges-protein-and-chemical-space-massive-protein|https://ir.recursion.com|Aug 08, 2023
Recursion|Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results|https://ir.recursion.com/news-releases/news-release-details/recursion-provides-business-updates-and-reports-second-quarter-0|https://ir.recursion.com|Aug 08, 2023
Recursion|Recursion to Participate in Upcoming Investor Conference|https://ir.recursion.com/news-releases/news-release-details/recursion-participate-upcoming-investor-conference-3|https://ir.recursion.com|Aug 01, 2023
Recursion|Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships|https://ir.recursion.com/news-releases/news-release-details/recursion-launches-valence-labs-icml-commitment-open-science|https://ir.recursion.com|Jul 26, 2023
Recursion|Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery|https://ir.recursion.com/news-releases/news-release-details/recursion-announces-collaboration-and-50-million-investment|https://ir.recursion.com|Jul 12, 2023
Recursion|Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem|https://ir.recursion.com/news-releases/news-release-details/recursion-celebrates-opening-its-canadian-headquarters-toronto|https://ir.recursion.com|Jun 26, 2023
Recursion|Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled|https://ir.recursion.com/news-releases/news-release-details/recursions-phase-2-trial-treatment-cerebral-cavernous|https://ir.recursion.com|Jun 13, 2023
Recursion|Recursion to Participate in Upcoming Investor Conferences|https://ir.recursion.com/news-releases/news-release-details/recursion-participate-upcoming-investor-conferences-8|https://ir.recursion.com|Jun 01, 2023
Recursion|Altitude Lab Relocates to Gateway’s BioHive Hub|https://ir.recursion.com/news-releases/news-release-details/altitude-lab-relocates-gateways-biohive-hub|https://ir.recursion.com|May 25, 2023
Recursion|Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer|https://ir.recursion.com/news-releases/news-release-details/recursion-appoints-david-mauro-md-phd-chief-medical-officer|https://ir.recursion.com|May 16, 2023
Peptone|Peptone presenting at Swiss Biotech Day 2023|https://peptone.io/conference/peptone-presenting-at-swiss-biotech-day-2023/|https://peptone.io|
Gen1e Lifescience|NewsDr. Sham Dholakia joins GEn1E Lifesciences as Chief Medical Officer, as it further scales its AI/ML platform, portfolio and partnerships|https://www.marketwatch.com/press-release/dr-sham-dholakia-joins-gen1e-lifesciences-as-chief-medical-officer-as-it-further-scales-its-aiml-platform-portfolio-and-partnerships-2022-12-14?mod=search_headline|https://www.gen1e.com|May 16, 2020
Gen1e Lifescience|Publication by Advisorp38 MAPK inhibition: A promising therapeutic approach for COVID-19Grimes, J. M., & Grimes, K. V.May 16, 2020|https://pubmed.ncbi.nlm.nih.gov/32422320/|https://www.gen1e.com|May 16, 2020
Schrodinger|Small                                                                                         Molecule Drug Discovery Events|https://www.schrodinger.com/upcoming-scientific-events?f%5B0%5D=field_platform_term%3A1869&f%255B0%255D=field_platform_term%3A1869|https://ir.schrodinger.com|
Schrodinger|Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-inducement-grants-under-nasdaq-listing-21|https://ir.schrodinger.com|Aug 11, 2023
Schrodinger|Schrödinger Reports Second Quarter 2023 Financial Results|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-second-quarter-2023-financial-results|https://ir.schrodinger.com|Aug 02, 2023
Schrodinger|Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-inducement-grants-under-nasdaq-listing-20|https://ir.schrodinger.com|Jul 20, 2023
Schrodinger|Schrödinger to Announce Second Quarter 2023 Financial Results on August 2|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-announce-second-quarter-2023-financial-results|https://ir.schrodinger.com|Jul 19, 2023
Schrodinger|Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-inducement-grants-under-nasdaq-listing-19|https://ir.schrodinger.com|Jun 22, 2023
Schrodinger|Schrödinger to Present at Goldman Sachs 44th Annual Global Healthcare Conference|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-present-goldman-sachs-44th-annual-global-healthcare|https://ir.schrodinger.com|Jun 01, 2023
Schrodinger|Schrödinger to Present at Jefferies Global Biopharma Conference|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-present-jefferies-global-biopharma-conference|https://ir.schrodinger.com|May 26, 2023
Schrodinger|Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-inducement-grants-under-nasdaq-listing-18|https://ir.schrodinger.com|May 25, 2023
Schrodinger|Schrödinger Reports Strong First Quarter 2023 Financial Results|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-reports-strong-first-quarter-2023-financial-results|https://ir.schrodinger.com|May 04, 2023
Schrodinger|Schrödinger Publishes Inaugural Corporate Sustainability Report|https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-publishes-inaugural-corporate-sustainability-report|https://ir.schrodinger.com|Apr 27, 2023
Isomorphic Labs|Blog15.8.23 By Max Jaderberg, Director of Machine Learning Modelling the invisible world of Molecular Biology with Machine Learningread more0a--upnone|https://www.isomorphiclabs.com/articles/modelling-the-invisible-world-of-molecular-biology-with-machine-learning|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog18.7.23 By Kate Parkyn, Talent Director How to get a job at Isomorphic Labsread more|https://www.isomorphiclabs.com/articles/how-to-get-a-job-at-isomorphic-labs|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog27.6.23 By Isomorphic Labs Colleagues Why I: Isomorphic Labs colleagues share what attracted them and inspires their workread more|https://www.isomorphiclabs.com/articles/why-i-isomorphic-labs-colleagues-share-what-attracted-them-and-inspires-their-work|https://www.isomorphiclabs.com|
Isomorphic Labs|News31.5.23 By Isomorphic Labs Isomorphic Labs Announces New Lausanne Location read more|https://www.isomorphiclabs.com/articles/isomorphic-labs-has-announced-the-opening-of-its-new-offices-in-lausanne-switzerland|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog25.4.23 By Miles Congreve, Chief Scientific Officer âIt's both humbling and exciting to adopt a beginnerâs mindsetâ - Having permission to be wrongread more|https://www.isomorphiclabs.com/articles/its-both-humbling-and-exciting-to-adopt-a-beginners-mindset-having-permission-to-be-wrong|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog4.4.23 By Isomorphic Labs Colleagues Why I: Isomorphic Labs colleagues share why they joined the companyread more|https://www.isomorphiclabs.com/articles/why-i-isomorphic-labs-collegues-share-why-they-joined-the-company|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog8.3.23 By Caroline Low, Distinguished Researcher Breaking barriers and building bridges with purposeread more|https://www.isomorphiclabs.com/articles/we-can-only-innovate-with-collaboration-creativity-and-chemistry|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog31.1.23 By Sergei Yakneen, Chief Technology Officer  âOnce in a lifetime - or neverâ - Reflections from year one at Isomorphic Labsread more|https://www.isomorphiclabs.com/articles/once-in-a-lifetime-or-never-reflections-from-year-one-at-isomorphic-labs|https://www.isomorphiclabs.com|
Isomorphic Labs|News9.1.23 By  Isomorphic Labs announces new Scientific Advisory Boardread more|https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-new-scientific-advisory-board|https://www.isomorphiclabs.com|
Isomorphic Labs|News1.5.22 By  Isomorphic Labs announces first phase of management teamread more|https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-first-phase-of-management-team|https://www.isomorphiclabs.com|
Isomorphic Labs|Blog1.11.21 By Demis Hassabis Introducing Isomorphic Labsread more|https://www.isomorphiclabs.com/articles/introducing-isomorphic-labs|https://www.isomorphiclabs.com|
Charm Therapeutics|CHARM Therapeutics Receives Investment for Deep Learning-enabled Drug Discovery Research from NVIDIA|https://charmtx.com/charm-therapeutics-receives-investment-for-deep-learning-enabled-drug-discovery-research-from-nvidia/|https://charmtx.com|May 15, 2023
Charm Therapeutics|CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs|https://charmtx.com/collaboration-with-bristol-myers-squibb-to-enable-and-accelerate-small-molecule-drug-discovery-programs/|https://charmtx.com|March 20, 2023
Charm Therapeutics|CHARM Therapeutics Strengthens Leadership Team with Key Appointments to Support Drug Discovery and Development Capability|https://charmtx.com/charm-therapeutics-strengthens-leadership-team-with-key-appointments-to-support-drug-discovery-and-development-capability/|https://charmtx.com|January 4, 2023
Charm Therapeutics|CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology|https://charmtx.com/charm-therapeutics-launches-with-a-50-million-series-a-financing-to-transform-structure-based-drug-discovery-using-its-proprietary-dragonfold-ai-technology/|https://charmtx.com|June 9, 2022
Endpoint Health (Private)|Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases Press Release|https://endpointhealth.com/news/endpoint-health-unveils-precision-immunology-program-to-address-tissue-factor-mediated-inflammation-in-autoimmune-diseases/|https://endpointhealth.com|October 4, 2022
Endpoint Health (Private)|Endpoint Health Named to Y Combinator’s Top Companies List Press Release|https://endpointhealth.com/news/endpoint-health-named-to-y-combinators-top-companies-list/|https://endpointhealth.com|August 23, 2022
Endpoint Health (Private)|Endpoint Health Raises $52 Million in Financing to Expand and Progress Precision Immunology Pipeline Press Release|https://endpointhealth.com/news/endpoint-health-raises-52-million-in-financing-to-expand-and-progress-precision-immunology-pipeline/|https://endpointhealth.com|June 2, 2022
Endpoint Health (Private)|Endpoint Health Presents New Research at Society of Critical Care Medicine’s 2022 Critical Care Congress, Predicting Outcomes for Common Treatment Strategies in ARDS Press Release|https://endpointhealth.com/news/endpoint-health-presents-new-research-at-society-of-critical-care-medicines-2022-critical-care-congress-predicting-outcomes-for-common-treatment-strategies-in-ards/|https://endpointhealth.com|April 19, 2022
Endpoint Health (Private)|Endpoint Health Announces Results from Retrospective Analyses Evaluating the Corticosteroid Response in Patients with Septic Shock, based on  Novel Gene Expression Scoring Model Press Release|https://endpointhealth.com/news/endpoint-health-announces-results-from-retrospective-analyses-evaluating-the-corticosteroid-response-in-patients-with-septic-shock-based-on-novel-gene-expression-scoring-model/|https://endpointhealth.com|February 28, 2022
Endpoint Health (Private)|Endpoint Health Enters into Global Collaboration and Licensing Agreement with Grifols Press Release|https://endpointhealth.com/news/endpoint-health-enters-into-global-collaboration-and-licensing-agreement-with-grifols/|https://endpointhealth.com|February 24, 2022
Endpoint Health (Private)|Endpoint Health Presents Published Results from a Retrospective Study of Adult ARDS Patients, Identifying an Innovative Approach to Predicting Clinical Outcomes Press Release|https://endpointhealth.com/news/endpoint-health-presents-published-results-from-a-retrospective-study-of-adult-ards-patients-identifying-an-innovative-approach-to-predicting-clinical-outcomes/|https://endpointhealth.com|January 6, 2022
Endpoint Health (Private)|Precision-First Therapeutics: A Podcast with Diego Rey Podcast|https://endpointhealth.com/news/precision-first-therapeutics-a-podcast-with-diego-rey/|https://endpointhealth.com|December 9, 2021
Endpoint Health (Private)|Healthcare Pioneers Share Secrets to Building Iconic Engineering Biology Companies Article|https://endpointhealth.com/news/healthcare-pioneers-share-secrets-to-building-iconic-engineering-biology-companies/|https://endpointhealth.com|November 19, 2021
Endpoint Health (Private)|ENDPOINT HEALTH INC. 855 El Camino Real 13A Palo Alto, CA 94301|https://goo.gl/maps/4bubfZDAhpC4P1aPA|https://endpointhealth.com|
Endpoint Health (Private)|Do not sell my personal information|https://endpointhealth.comjavascript:void(0)|https://endpointhealth.com|
Odyssey Therapeutics (Private)|Odyssey Therapeutics Named to 2022 Endpoints 11 Learn More|https://odysseytx.com/odyssey-therapeutics-named-to-2022-endpoints-11/|https://odysseytx.com|
Kinnate Biopharma|Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-reports-second-quarter-2023-financial|https://investors.kinnate.com|Aug 08, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-participate-upcoming-investor-2|https://investors.kinnate.com|Jun 01, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-reports-first-quarter-2023-financial|https://investors.kinnate.com|May 11, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-adds-two-new-drug-candidates-its-growing|https://investors.kinnate.com|Apr 17, 2023
Kinnate Biopharma|First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma|https://investors.kinnate.com/news-releases/news-release-details/first-report-positive-dose-escalation-data-supports-best-class|https://investors.kinnate.com|Apr 17, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-provides-full-year-2022-financial-results|https://investors.kinnate.com|Mar 15, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-report-first-clinical-data-its|https://investors.kinnate.com|Mar 14, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Provides Statement on Silicon Valley Bank Receivership|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-provides-statement-silicon-valley-bank|https://investors.kinnate.com|Mar 12, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-announces-acquisition-ownership-stake|https://investors.kinnate.com|Feb 21, 2023
Kinnate Biopharma|Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor|https://investors.kinnate.com/news-releases/news-release-details/kinnate-biopharma-inc-receives-fast-track-designation-us-food-0|https://investors.kinnate.com|Feb 14, 2023
Vibliome Therapeutics (Private)|Vibliome Therapeutics and AssayQuant Technologies, Inc. Establish Collaborative Relationship|https://vibliome.com/assets/vibliome_news_aug_2_2022.pdf|https://vibliome.com|
Vibliome Therapeutics (Private)|Vibliome Therapeutics Spins Off New Company, Raises Additional Funding|https://vibliome.com/assets/vibliome_news_feb_23_2022.pdf|https://vibliome.com|February 24, 2022
Vibliome Therapeutics (Private)|Vibliome Therapeutics Expands Its Kinase Inhibitor Discovery Library|https://vibliome.com/assets/vibliome_news_january_11_2021.pdf|https://vibliome.com|January 11, 2021
Vibliome Therapeutics (Private)|Vibliome Therapeutics Closes First Tranche of Its $16 million Series A Financing Round to Advance Selective Kinase Inhibitor Technology for Oncology and Other Disease Applications|https://vibliome.com/assets/vibliome_news_april_29_2019.pdf|https://vibliome.com|April 29, 2019
Theseus Pharma|Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results|https://ir.theseusrx.com/2023-08-10-Theseus-Pharmaceuticals-Announces-Business-Highlights-and-Reports-Second-Quarter-2023-Financial-Results|https://ir.theseusrx.com|Aug 10, 2023
Theseus Pharma|Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST|https://ir.theseusrx.com/2023-07-13-Theseus-Pharmaceuticals-to-Discontinue-Enrollment-in-Phase-1-2-Study-and-Terminate-Development-of-THE-630-in-Patients-with-GIST|https://ir.theseusrx.com|Jul 13, 2023
Theseus Pharma|Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference|https://ir.theseusrx.com/2023-05-31-Theseus-Pharmaceuticals-to-Participate-in-the-Jefferies-Healthcare-Conference|https://ir.theseusrx.com|May 31, 2023
Theseus Pharma|Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST|https://ir.theseusrx.com/2023-05-25-Theseus-Pharmaceuticals-Reports-Initial-Dose-Escalation-Data-from-Ongoing-Phase-1-2-Trial-of-THE-630-in-Patients-with-Advanced-GIST|https://ir.theseusrx.com|May 25, 2023
Theseus Pharma|Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results|https://ir.theseusrx.com/2023-05-11-Theseus-Pharmaceuticals-Announces-Business-Highlights-and-Reports-First-Quarter-2023-Financial-Results|https://ir.theseusrx.com|May 11, 2023
Enliven Therapeutics|Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress|https://ir.enliventherapeutics.com/news-releases/news-release-details/enliven-therapeutics-reports-second-quarter-2023-financial|https://ir.enliventherapeutics.com|August 10, 2023
Enliven Therapeutics|Enliven Therapeutics to Present at Two Upcoming Investor Conferences|https://ir.enliventherapeutics.com/news-releases/news-release-details/enliven-therapeutics-present-two-upcoming-investor-conferences|https://ir.enliventherapeutics.com|May 31, 2023
Enliven Therapeutics|Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results|https://ir.enliventherapeutics.com/news-releases/news-release-details/enliven-therapeutics-highlights-business-achievements-and|https://ir.enliventherapeutics.com|May 11, 2023
Enliven Therapeutics|Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million|https://ir.enliventherapeutics.com/news-releases/news-release-details/enliven-therapeutics-closes-merger-imara-and-private-placement|https://ir.enliventherapeutics.com|February 23, 2023
Kronos Bio|Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-departure-chief-financial-officer-and-head|https://ir.kronosbio.com|Aug 17, 2023
Kronos Bio|Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-second-quarter-1|https://ir.kronosbio.com|Aug 08, 2023
Kronos Bio|Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-names-marc-besman-phd-senior-vice-president|https://ir.kronosbio.com|Jun 06, 2023
Kronos Bio|Kronos Bio Announces Participation in Upcoming Investor Conferences|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-participation-upcoming-investor-4|https://ir.kronosbio.com|Jun 01, 2023
Kronos Bio|Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-first-quarter-1|https://ir.kronosbio.com|May 10, 2023
Kronos Bio|Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-appoints-roger-dansey-md-board-directors|https://ir.kronosbio.com|Apr 24, 2023
Kronos Bio|Kronos Bio Announces Changes to Board of Directors|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-changes-board-directors|https://ir.kronosbio.com|Apr 11, 2023
Kronos Bio|Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-recent-business-progress-and-fourth-quarter-1|https://ir.kronosbio.com|Mar 15, 2023
Kronos Bio|Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-participation-43rd-annual-cowen-health-care|https://ir.kronosbio.com|Feb 28, 2023
Kronos Bio|Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology|https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-announces-discovery-collaboration-genentech-advance|https://ir.kronosbio.com|Jan 09, 2023
Kronos Bio|UK and EU Privacy Contacts|https://kronosbio.com/privacycontacts/|https://ir.kronosbio.com|
Kymera Therapeutics|Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-second-quarter-2023-financial|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-report-second-quarter-2023-financial-results|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-receives-fda-orphan-drug-designation-kt-253|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-stat3-degrader-kt-333-and-irakimid-degrader|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-updated-clinical-data-phase-1|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-data-demonstrating-superior|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics to Participate in Upcoming June Investor Conference|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-participate-upcoming-june-investor|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer|https://investors.kymeratx.com/news-releases/news-release-details/kymera-appoints-jeremy-chadwick-phd-chief-operating-officer|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics Doses First Patient in Phase 1 Oncology Trial of MDM2 Degrader KT-253|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-doses-first-patient-phase-1-oncology-trial|https://investors.kymeratx.com|
Kymera Therapeutics|Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium|https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-clinical-data-phase-1-trial-irak4|https://investors.kymeratx.com|
Vera Therapeutics|Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-provides-business-update-and-reports-second-0|https://ir.veratx.com|August 10, 2023
Vera Therapeutics|Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-positive-week-36-efficacy-and-safety|https://ir.veratx.com|June 17, 2023
Vera Therapeutics|Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-host-presentation-week-36-data-phase-2b-origin|https://ir.veratx.com|June 15, 2023
Vera Therapeutics|Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-participate-44th-annual-goldman-sachs-global|https://ir.veratx.com|June 8, 2023
Vera Therapeutics|Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-initiates-pivotal-phase-3-origin-3-clinical|https://ir.veratx.com|June 7, 2023
Vera Therapeutics|Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-provides-business-update-and-reports-first-0|https://ir.veratx.com|May 11, 2023
Vera Therapeutics|Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-appoints-kerry-cooper-md-senior-vice-president|https://ir.veratx.com|May 4, 2023
Vera Therapeutics|Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-provides-business-update-and-reports-fourth|https://ir.veratx.com|March 28, 2023
Vera Therapeutics|Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-participate-cowen-43rd-annual-health-care|https://ir.veratx.com|February 27, 2023
Vera Therapeutics|Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock|https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-closing-upsized-public-offering-and|https://ir.veratx.com|February 6, 2023
Fulcrum Therapeutics|FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease|https://ir.fulcrumtx.com/news-releases/news-release-details/fda-lifts-clinical-hold-fulcrum-therapeutics-ftx-6058-sickle|https://ir.fulcrumtx.com|Aug 22, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-7|https://ir.fulcrumtx.com|Aug 11, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-recent-business-highlights-and-2|https://ir.fulcrumtx.com|Aug 03, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Appoints Chief Financial Officer|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-appoints-chief-financial-officer|https://ir.fulcrumtx.com|Aug 03, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-host-second-quarter-2023-financial-results|https://ir.fulcrumtx.com|Jul 27, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-signs-exclusive-global-license-agreement|https://ir.fulcrumtx.com|Jul 10, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-6|https://ir.fulcrumtx.com|Jul 07, 2023
Fulcrum Therapeutics|Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)|https://ir.fulcrumtx.com/news-releases/news-release-details/advocacy-and-industry-partners-launch-new-global-coalition-speed|https://ir.fulcrumtx.com|Jun 20, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-reports-inducement-grants-under-nasdaq-5|https://ir.fulcrumtx.com|Jun 09, 2023
Fulcrum Therapeutics|Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023|https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-recent-business-highlights-and-1|https://ir.fulcrumtx.com|May 15, 2023
Fulcrum Therapeutics|Code of Conduct & Business Ethics|https://ir.fulcrumtx.com/static-files/c7600013-60d2-42ec-afc5-902021f9beb9|https://ir.fulcrumtx.com|
Biosplice Therapeutics (Private)|Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial|https://www.biosplice.com/medium/image/biosplice-announces-interim-data-from-phase-3-long-term-extension-clinical-trial-in-knee-osteoarthri_929/view.aspx|https://www.biosplice.com|
Biosplice Therapeutics (Private)|First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology|https://www.biosplice.com/medium/image/first-subject-dosed-in-biosplice-therapeutics-phase-1b-clinical-trial-in-oncology_914/view.aspx|https://www.biosplice.com|
Biosplice Therapeutics (Private)|Darrin M. Beaupre, M.D., Ph.D. joins Biosplice as Chief Medical Officer, Oncology|https://www.biosplice.com/medium/image/darrin-m-beaupre-md-phd-joins-samumed-as-chief-medical-officer-oncology_843/view.aspx|https://www.biosplice.com|
BioAge Labs (Private)|BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer|https://www.businesswire.com/news/home/20230522005214/en/BioAge-Labs-Appoints-BJ-Sullivan-as-Chief-Strategy-Officer|https://bioagelabs.com|
BioAge Labs (Private)|BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences|https://www.businesswire.com/news/home/20230426005064/en/BioAge-Labs-to-Present-on-Therapeutics-for-Brain-Aging-Targeting-NLRP3-Apelin-and-Other-Novel-Pathways-at-Upcoming-International-Conferences|https://bioagelabs.com|April 26, 2023
BioAge Labs (Private)|BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest|https://www.businesswire.com/news/home/20221205005201/en/BioAge-Announces-Positive-Topline-Results-for-BGE-105-in-Phase-1b-Clinical-Trial-Evaluating-Muscle-Atrophy-in-Older-Volunteers-at-Bed-Rest|https://bioagelabs.com|December 5, 2022
BioAge Labs (Private)|BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences|https://www.businesswire.com/news/home/20221013005356/en/BioAge-Labs-to-Present-Data-on-Novel-Brain-Penetrant-NLRP3-Inhibitors-for-Treatment-of-Neurodegeneration-and-Brain-Aging-at-Upcoming-Conferences|https://bioagelabs.com|October 13, 2022
Aclaris Therapeutics|Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-second-quarter-2023-financial|https://investor.aclaristx.com|August 7, 2023
Aclaris Therapeutics|Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-completes-enrollment-phase-2b-study-oral|https://investor.aclaristx.com|June 13, 2023
Aclaris Therapeutics|Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-participate-two-june-healthcare-investor|https://investor.aclaristx.com|June 2, 2023
Aclaris Therapeutics|Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-first-quarter-2023-financial|https://investor.aclaristx.com|May 8, 2023
Aclaris Therapeutics|Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announce-first-quarter-2023-financial|https://investor.aclaristx.com|May 2, 2023
Aclaris Therapeutics|Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-participate-hc-wainwright-autoimmune|https://investor.aclaristx.com|March 27, 2023
Aclaris Therapeutics|Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-preliminary-topline-data-12-week|https://investor.aclaristx.com|March 6, 2023
Aclaris Therapeutics|Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-reports-fourth-quarter-and-full-year-2022|https://investor.aclaristx.com|February 23, 2023
Aclaris Therapeutics|Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-participate-virtual-svb-securities-global|https://investor.aclaristx.com|February 9, 2023
Aclaris Therapeutics|Aclaris Therapeutics Provides 2023 Outlook|https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-provides-2023-outlook|https://investor.aclaristx.com|January 6, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-announces-dosing-10th-patient-ongoing|https://ir.eledon.com|August 16, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-second-quarter-2023-operating-and|https://ir.eledon.com|August 10, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-present-jefferies-healthcare-conference-0|https://ir.eledon.com|June 02, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-first-quarter-2023-operating-and|https://ir.eledon.com|May 11, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-report-first-quarter-2023-financial|https://ir.eledon.com|May 11, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-announces-185-million-financing-advance|https://ir.eledon.com|May 01, 2023
Eledon Pharmaceuticals|Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology|https://ir.eledon.com/news-releases/news-release-details/eledon-reports-data-ongoing-phase-1b-trial-evaluating|https://ir.eledon.com|March 31, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-reports-fourth-quarter-and-full-year-2022|https://ir.eledon.com|March 30, 2023
Eledon Pharmaceuticals|Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023|https://ir.eledon.com/news-releases/news-release-details/eledon-pharmaceuticals-report-fourth-quarter-and-full-year-2022|https://ir.eledon.com|March 30, 2023
Eledon Pharmaceuticals|Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023|https://ir.eledon.com/news-releases/news-release-details/eledon-present-data-ongoing-phase-1b-trial-evaluating|https://ir.eledon.com|March 23, 2023
Arcutis Biotherapeutics|April 18, 2023 Featured  Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older   Read More|https://www.arcutis.com/arcutis-announces-fda-acceptance-of-new-drug-application-for-roflumilast-foam-0-3-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/|https://www.arcutis.com|April 18, 2023
Arcutis Biotherapeutics|September 20, 2022 Featured  Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis   Read More|https://www.arcutis.com/journal-of-the-american-medical-association-publishes-roflumilast-cream-0-3-results-from-pivotal-dermis-1-and-2-phase-3-trials-in-plaque-psoriasis/|https://www.arcutis.com|September 20, 2022
Arcutis Biotherapeutics|July 29, 2022 Featured  FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older   Read More|https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older/|https://www.arcutis.com|July 29, 2022
Arcutis Biotherapeutics|August 18, 2023  Arcutis Appoints Interim Chief Financial Officer (CFO)   Read More|https://www.arcutis.com/arcutis-appoints-interim-chief-financial-officer-cfo/|https://www.arcutis.com|August 18, 2023
Arcutis Biotherapeutics|August 10, 2023  Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for  Topical Roflumilast in Greater China and Southeast Asia   Read More|https://www.arcutis.com/arcutis-and-huadong-announce-strategic-collaboration-and-licensing-agreement-for-topical-roflumilast-in-greater-china-and-southeast-asia/|https://www.arcutis.com|August 10, 2023
Arcutis Biotherapeutics|August 8, 2023  Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update   Read More|https://www.arcutis.com/arcutis-announces-second-quarter-2023-financial-results-and-provides-business-update/|https://www.arcutis.com|
Arcutis Biotherapeutics|August 4, 2023  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Read More|https://www.arcutis.com/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-16/|https://www.arcutis.com|
Arcutis Biotherapeutics|July 24, 2023  Arcutis to Report Second Quarter Financial Results   Read More|https://www.arcutis.com/arcutis-to-report-second-quarter-financial-results/|https://www.arcutis.com|July 24, 2023
Arcutis Biotherapeutics|July 17, 2023  Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark   Read More|https://www.arcutis.com/arcutis-announces-zoryve-roflumilast-cream-0-3-has-been-included-in-a-preferred-position-on-national-formularies-for-cvs-caremark/|https://www.arcutis.com|July 17, 2023
Arcutis Biotherapeutics|July 5, 2023  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Read More|https://www.arcutis.com/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-15/|https://www.arcutis.com|
Arcutis Biotherapeutics|June 6, 2023  Arcutis to Present at Upcoming Investor Conference   Read More|https://www.arcutis.com/arcutis-to-present-at-upcoming-investor-conference-6/|https://www.arcutis.com|
Arcutis Biotherapeutics|June 5, 2023  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Read More|https://www.arcutis.com/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14/|https://www.arcutis.com|
Arcutis Biotherapeutics|May 24, 2023  Arcutis Announces Leadership Transition   Read More|https://www.arcutis.com/arcutis-announces-leadership-transition/|https://www.arcutis.com|May 24, 2023
Arcutis Biotherapeutics|May 9, 2023  Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update   Read More|https://www.arcutis.com/arcutis-announces-first-quarter-2023-financial-results-and-provides-business-update/|https://www.arcutis.com|
Arcutis Biotherapeutics|May 5, 2023  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Read More|https://www.arcutis.com/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-13/|https://www.arcutis.com|
